Because monoclonal antibodies are the foundation of QED's business, we never stop looking for new ways to improve our procedures for creating hybridomas and producing antibodies. As a result, our scientists continually evaluate key reagents from multiple suppliers and use only those that support the greatest yields of hybridoma cell lines and antibody products. We now make these pre-screened reagents available to our customers in QED Antibody Production Kits.
